Physician profile
Ruby Annette Gomez
NPI 1821595265
$13,144.39
in general payments reported to CMS, 2019-2025
45 companies · $4,500 in 2025
The $4,500 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,629 · 2022: $1,364 · 2023: $2,553 · 2024: $3,097 · 2025: $4,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,326 · Education: $723 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,326.11 |
| Education | $723.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,583.27 | 2021-2025 | Breztri, Farxiga, Lynparza |
| Janssen Biotech, INC. | $1,210.07 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| Novo Nordisk INC | $1,058.70 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $926.38 | 2023-2025 | Opdivo, Reblozyl, Camzyos |
| Amgen INC. | $819.52 | 2021-2023 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $793.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $707.04 | 2021-2025 | |
| Exelixis INC. | $540.37 | 2023-2025 | Cabometyx |
| Daiichi Sankyo INC. | $537.59 | 2024-2025 | Enhertu, Vanflyta, Datroway |
| Pfizer INC. | $465.12 | 2023-2025 | |
| Gilead Sciences, INC. | $439.09 | 2024-2025 | Trodelvy |
| Incyte Corporation | $430.09 | 2024-2025 | Monjuvi |
| Genzyme Corporation | $398.61 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.96 | 2021-2023 | Jardiance |
| Sobi, INC | $264.45 | 2024-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.